Cj. Mcginn et al., LEUCOVORIN MODULATION OF 5-IODODEOXYURIDINE RADIOSENSITIZATION - A PHASE-I STUDY, Clinical cancer research, 2(8), 1996, pp. 1299-1305
Evidence for clinically significant radiosensitization by the halogena
ted pyrimidine 5-iododeoxyuridine (IdUrd) continues to accumulate, In
vitro radiosensitization has been demonstrated in human colon tumor ce
ll lines following exposure to 1-10 mu M. Coadministration of leucovor
in (LV) increases radiosensitization, which correlates directly with i
ncreased IdUrd DNA incorporation, Clinical data regarding proliferatio
n rates and thymidine kinase levels in tumors versus normal tissues su
ggest selective incorporation of IdUrd into gastrointestinal tumors ma
y occur, The objectives of this Phase I study were: (a) to assess the
feasibility of LV modulation of IdUrd radiosensitization by determinin
g the maximum tolerated dose (MTD) of IdUrd plus LV; and (b) to perfor
m correlative laboratory studies to investigate the potential of IdUrd
plus LV to increase radiosensitization in vivo, Seventeen patients wi
th unresectable or recurrent gastrointestinal adenocarcinomas received
a 14-day course of continuous i,v, infusion of IdUrd prior to initiat
ion of radiotherapy, Two additional 14-day infusions of IdUrd with LV
were given during the course of radiotherapy (60 Gy in 6 weeks), The i
nitial dose of IdUrd was 250 mg/m(2)/day and was escalated in subseque
nt patients to 400 and 600 mg/m(2)/day, The LV dose remained fixed at
250 mg/m(2)/day, Leukopenia was the dose-limiting toxicity, and 400 mg
/m(2)/day was the MTD for this trial, At the MTD, the mean +/- SD stea
dy-state plasma concentration of IdUrd during the infusion, measured b
y high-performance liquid chromatography, was 0.66 +/- 0.23 mu M. Ther
e was no significant influence of LV on IdUrd DNA incorporation in per
ipheral blood granulocytes as measured by high-performance liquid chro
matography, Based on toxicity data and correlative laboratory studies,
a meaningful increase in radiosensitization would not be achieved wit
h the IdUrd infusion schedule and dose of LV investigated compared wit
h IdUrd alone.